Headquarters: Cambridge, Massachusetts, USA
Ticker: CERE (NASDAQ)
Founded: 2020 (spun off from Pfizer)
Pipeline Focus: Parkinson's Disease disease, epilepsy, mood disorders
Cerevel Therapeutics is a neuroscience-focused biotechnology company that was spun off from Pfizer in 2020 and went public in 2021. The company leverages its deep expertise in receptor selectivity and brain penetration to develop novel therapies for neurological and psychiatric disorders. Cerevel's lead program, CVN424, represents a novel approach to Parkinson's Disease disease treatment through selective dopamine D1/D5 receptor activation[1].
Cerevel's pipeline focuses on areas of high unmet need in neuroscience, including movement disorders, epilepsy, and mood disorders. The company's strategy combines internal discovery with strategic partnerships to advance its portfolio of novel molecules with differentiated pharmacology^2].
Mechanism: Selective dopamine D1 receptor partial agonist and D5 receptor agonist
Stage: Phase 2
Status: Clinical
CVN424 represents a novel approach to treating Parkinson's Disease disease motor symptoms through selective activation of dopamine D1 and D5 receptors. Unlike current dopamine agonists that broadly stimulate dopamine receptors, CVN424's selectivity profile may provide motor symptom relief with potentially reduced side effects including dyskinesia^3].
Clinical Development:
Differentiation:
Mechanism: Undisclosed CNS target
Stage: Phase 1
Status: Clinical
CVN231 is Cerevel's second Parkinson's Disease disease program, currently in Phase 1 clinical trials. Additional details about the mechanism and target remain undisclosed^4].
Cerevel's dopamine-focused pipeline has potential relevance to Multiple System Atrophy:
| Program | Mechanism | Stage |
|---|---|---|
| CVL-231 | Kv7.2/7.3 potassium channel opener | Phase 2 |
| Undisclosed | Anti-seizure | Discovery |
| Program | Mechanism | Stage |
|---|---|---|
| CVL-231 | M4 muscarinic agonist | Phase 2 |
| CVL-561 | Undisclosed | Phase 1 |
Cerevel was spun off from Pfizer with a strategic partnership that includes:
Cerevel's drug discovery platform focuses on: